Related Experiment Video
Updated: Jul 16, 2025

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
miRNAs and Multiple Myeloma: Focus on the Pathogenesis, Prognosis, and Drug Resistance
Ali Tavakoli Pirzaman1, Pouyan Ebrahimi1, Amir Hossein Hasanpour1
1Student Research Committee, Babol University of Medical Sciences, Babol, Iran.
Abstract:
Multiple myeloma (MM) produces clonal plasma cells and aberrant monoclonal antibody accumulation in patients' bone marrow (BM). Around 1% of all cancers and 13% of hematological malignancies are caused by MM, making it one of the most common types of cancer. Diagnostic and therapeutic methods for managing MM are currently undergoing extensive research. MicroRNAs (miRNAs) are short noncoding RNAs that reduce or inhibit the translation of their target mRNA after transcription. Because miRNAs play an influential role in how myeloma develops, resources, and becomes resistant to drugs, miRNA signatures may be used to diagnose, do prognosis, and treat the myeloma response. Consequently, researchers have investigated the levels of miRNA in plasma cells from MM patients and developed tools to test whether they directly impacted tumor growth. This review discusses the latest discoveries in miRNA science and their role in the development of MM. We also emphasize the potential applications of miRNAs to diagnose, prognosticate, and treat MM in the future.
More Related Videos
Related Concept Videos
MicroRNAs
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation

